there are some heavy hitters with significant stakes in this name (and these investors are not clueless hedge funds like Efficacy Capital, the RPRX shareholder).
I have never seen any investor in biotech whose coat-tails I would want to ride. And I've looked at a bunch. Big and small. So I consider it a non-event to name investors regardless of 'size' and 'name recognition'.
Market Data 
Markets 
AI
